Mycophenolate Mofetil use is associated with prolonged graft survival after kidney transplantation.

A. Kainz(1,2), G. Heinze(3), R. Korbély(1), C. Schwarz(1), R. Oberbauer(1,2,4)

1- Department of Nephrology, KH Elisabethinen, Linz, Austria

2- Department of Nephrology, Medical University Vienna, Austria

3- Core Unit of Medical Statistics and Informatics, Medical University Vienna, Vienna

4- Austrian Dialysis and Transplant Registry, Austria

STROBE-Checklist: PDF document.

 

// Tables
// Figures

Webtable 1:
Webtable 1:

List of all variables in the database used for analysis

View PDF

Webfigure 1:
Webfigure 1:

Kaplan-Meier plot of actual graft survival counting graft loss and death as event. The numbers below the x-axis refer to the subjects at risk at each time point. The p-value was derived from a log-rank test.

View PDF

Webfigure 2:
Webfigure 2:

Kaplan – Meier plot of patient survival. The numbers below the x-axis show the patients at risk at two years intervals. The p-value was derived from a log-rank test.

View PDF

Webtable 2:
Webtable 2:

Functional graft survival
Parameters used for propensity score model for functional graft survival

View PDF

Webfigure 3:
Webfigure 3:

Functional graft survival
Distribution of propensity score for functional graft survival of the groups MMF and AZA.

View PDF

Webtable 3:
Webtable 3:

Functional graft survival
Summary of the results derived from the five different analytical strategies analyzing the hazard of functional graft loss in the AZA vs MMF patients adjusted for several covariables.

View PDF

Webtable 4:
Webtable 4:

Actual graft survival
Parameters used for propensity score model for actual graft survival

View PDF

Webfigure 4:
Webfigure 4:

Actual graft survival
Distribution of propensity score for actual graft survival of the groups MMF and AZA.

View PDF

Webtable 5:
Webtable 5:

Actual graft survival
Summary of the results derived from the five different analytical strategies analyzing the hazard of actual graft loss in the AZA vs. MMF patients adjusted for several covariables.

View PDF

Webtable 6:
Webtable 6:

Patient survival
Parameters used for propensity score model patient survival

View PDF

Webfigure 5:
Webfigure 5:

Patient survival
Distribution of propensity score for patient survival of the groups MMF and AZA.

View PDF

Webtable 7:
Webtable 7:

Patient survival
Summary of the results derived from the five different analytical strategies analyzing the hazard of mortality in the AZA vs. MMF patients adjusted for several covariables.

View PDF

Webfigure 6:
Webfigure 6:

Schoenfeld residuals
Functional graft survival (CCO analysis)

View PDF

Webfigure 7:
Webfigure 7:

Schoenfeld residuals
Actual graft survival (CCO analysis)

View PDF

Webfigure 8:
Webfigure 8:

Schoenfeld residuals
Patient survival (CCO analysis)

View PDF

SCIENTIFIC COLLABORATIONS